2024
Complete vs. Incomplete Consolidative Radiotherapy in Patients with Extensive-Stage Small Cell Lung Cancer
Ninia J, Verma N, Laird J, Hayman T, Knowlton C, Peters G, Campbell A, Housri N, Feghali K, de Jong D, Park H. Complete vs. Incomplete Consolidative Radiotherapy in Patients with Extensive-Stage Small Cell Lung Cancer. International Journal Of Radiation Oncology • Biology • Physics 2024, 120: e51. DOI: 10.1016/j.ijrobp.2024.07.1890.Peer-Reviewed Original ResearchExtensive-stage small cell lung cancerProgression-free survivalSmall cell lung cancerOverall survivalCell lung cancerOligometastatic diseaseChemo-immunotherapyLung cancerSuperior progression-free survivalMedian follow-up timePatients treated with CCSites of disease involvementConsolidative thoracic radiotherapyAssociated with improved outcomesChemotherapy-based treatmentStratified Cox proportional hazard regressionsLog-rank testCox proportional hazards regressionDisease burdenTime of diagnosisKaplan-Meier estimatesProportional hazards regressionConsolidation radiotherapyPolymetastatic diseaseOligometastatic patientsRadioresistant Pulmonary Oligometastatic and Oligoprogressive Lesions From Nonlung Primaries: Impact of Histology and Dose-Fractionation on Local Control After Radiation Therapy
Verma N, Laird J, Moore N, Hayman T, Housri N, Peters G, Knowlton C, Jairam V, Campbell A, Park H. Radioresistant Pulmonary Oligometastatic and Oligoprogressive Lesions From Nonlung Primaries: Impact of Histology and Dose-Fractionation on Local Control After Radiation Therapy. Advances In Radiation Oncology 2024, 9: 101500. PMID: 38699671, PMCID: PMC11063223, DOI: 10.1016/j.adro.2024.101500.Peer-Reviewed Original ResearchLocal recurrence-free survivalNon-lung primaryAssociated with higher local recurrence-free survivalProgression-free survivalBiologically effective doseLocal controlRadioresistant metastasesOverall survivalPulmonary metastasesPrimary cancerColorectal carcinomaAssociated with superior local controlMultivariate analysisPatients treated with radiotherapyRisk of local recurrenceMedian follow-up timeMultivariable Cox proportional hazards regressionInferior local controlMedian total doseSuperior local controlAssociated with decreased riskImpact of histologyMetastasis-free survivalRecurrence-free survivalLocal failureDose-volume Predictors of Radiation Pneumonitis Following Thoracic Hypofractionated Radiotherapy
Sasse A, Oh P, Saeed N, Yang D, Hayman T, Knowlton C, Peters G, Campbell A, Laird J, Housri N, Park H. Dose-volume Predictors of Radiation Pneumonitis Following Thoracic Hypofractionated Radiotherapy. International Journal Of Radiation Oncology • Biology • Physics 2024, 118: e5. DOI: 10.1016/j.ijrobp.2023.10.054.Peer-Reviewed Original ResearchHypofractionated radiation therapyRisk of gradeUltra-central tumoursRadiation pneumonitisLung V20Lung V5Central tumorsMultivariable logistic regression analysisSingle health care systemDose-volume predictorsDosimetric risk factorsGrade 5 toxicitySimilar local controlDose-fractionation regimensProbability of gradeProximal tracheobronchial treeLogistic regression analysisMATERIAL/METHODSHealth care systemPrimary endpointOverall survivalHypofractionated radiotherapyMultivariable analysisLung doseThoracic tumorsDosimetric Factors Associated with Esophagitis Following Hypofractionated Radiotherapy to the Thorax
Sasse, Oh P, Saeed N, Yang D, Peters G, Hayman T, Housri N, Laird J, Campbell A, Knowlton C, Park H. Dosimetric Factors Associated with Esophagitis Following Hypofractionated Radiotherapy to the Thorax. International Journal Of Radiation Oncology • Biology • Physics 2024, 118: e7-e8. DOI: 10.1016/j.ijrobp.2023.10.059.Peer-Reviewed Original ResearchHypofractionated radiation therapyTotal patientsOverall survivalLocal controlUltra-central lung tumorsMultivariable logistic regression analysisSignificant differencesComparable local controlGrade 3 esophagitisRisk of gradeCases of gradeProbability of gradeLogistic regression analysisMATERIAL/METHODSMean esophagus doseSingle healthcare systemEsophagus DmaxPrimary endpointHypofractionated radiotherapyDosimetric factorsMultivariable analysisEsophagus doseThoracic tumorsDosimetric variablesClinical trials
2023
Dose-Volume Predictors of Radiation Pneumonitis After Thoracic Hypofractionated Radiation Therapy
Sasse A, Oh P, Saeed N, Yang D, Hayman T, Knowlton C, Peters G, Campbell A, Laird J, Housri N, Park H. Dose-Volume Predictors of Radiation Pneumonitis After Thoracic Hypofractionated Radiation Therapy. Practical Radiation Oncology 2023, 14: e97-e104. PMID: 37984711, DOI: 10.1016/j.prro.2023.11.006.Peer-Reviewed Original ResearchMean lung doseHypofractionated radiation therapyRisk of gradeRadiation pneumonitisLung V20Lung V5Dose-volume predictorsDosimetric risk factorsLogistic regression analysisGrade 5 casesSingle healthcare systemPrimary endpointDose regimensMultivariable analysisLung doseThoracic tumorsDosimetric variablesRisk factorsPneumonitisRadiation therapyCommon treatmentClinical practicePatientsSignificant associationPotential predictorsBilateral Breast Cancer With Contralateral Axillary Metastasis Warrants Aggressive Treatment: Let's Go for It!
Mokhtech M, Knowlton C. Bilateral Breast Cancer With Contralateral Axillary Metastasis Warrants Aggressive Treatment: Let's Go for It! International Journal Of Radiation Oncology • Biology • Physics 2023, 117: 527-528. PMID: 37739602, DOI: 10.1016/j.ijrobp.2023.03.039.Peer-Reviewed Original ResearchInterim Analysis of DD3: A Phase IB/II Trial of Dose-Deescalated 3-Fraction SBRT for Centrally Located Lung Cancer
Peters G, Cheng W, Boateng K, Knowlton C, Campbell A, Hayman T, Park H. Interim Analysis of DD3: A Phase IB/II Trial of Dose-Deescalated 3-Fraction SBRT for Centrally Located Lung Cancer. International Journal Of Radiation Oncology • Biology • Physics 2023, 117: e46-e47. DOI: 10.1016/j.ijrobp.2023.06.750.Peer-Reviewed Original ResearchStereotactic body radiation therapyPhase Ib/II trialCentral lung tumorsCancer-specific survivalProgression-free survivalLocal recurrenceLung tumorsInterim analysisII trialAdverse eventsOverall survivalDistant controlLocal controlGrade 2 adverse eventsUltra-central lung tumorsRisk dose constraintsRate of gradeSecondary lung tumorsCo-primary endpointsHigh toxicity ratesBiologically equivalent doseBody radiation therapyMATERIAL/METHODSRTOG 0236RTOG 0813Dose-Escalated vs. Conventional Hypofractionated Radiotherapy for Lung Cancer Patients in Predominantly Central Locations
Sasse A, Saeed N, Oh P, Housri N, Knowlton C, Hayman T, Peters G, Campbell A, Yang D, Park H. Dose-Escalated vs. Conventional Hypofractionated Radiotherapy for Lung Cancer Patients in Predominantly Central Locations. International Journal Of Radiation Oncology • Biology • Physics 2023, 117: e55. DOI: 10.1016/j.ijrobp.2023.06.768.Peer-Reviewed Original ResearchStereotactic body radiotherapyUltra-central tumoursHypofractionated radiation therapyHigh local controlOverall survivalGrade 3Local controlLung cancerNon-small cell lung cancerPromising local controlOutcomes of patientsEffective treatment regimenCell lung cancerHigher overall survivalLung cancer patientsMATERIAL/METHODSMedian ageHypofractionated radiotherapyTreatment regimenBody radiotherapyBaseline variablesCancer patientsTreatment optionsTumor locationChi-square analysisSurvival Outcomes for Oligometastatic vs. Polymetastatic Extensive-Stage Small Cell Lung Cancer Following Consolidative Thoracic Radiotherapy
Verma N, Ninia J, Hayman T, Housri N, Peters G, Knowlton C, Campbell A, Park H. Survival Outcomes for Oligometastatic vs. Polymetastatic Extensive-Stage Small Cell Lung Cancer Following Consolidative Thoracic Radiotherapy. International Journal Of Radiation Oncology • Biology • Physics 2023, 117: e68-e69. DOI: 10.1016/j.ijrobp.2023.06.797.Peer-Reviewed Original ResearchLocal recurrence-free survivalProgression-free survivalES-SCLC patientsES-SCLCOligometastatic diseaseOligometastatic patientsImproved OSLung involvementExtensive-stage small-cell lung cancerMultivariable Cox proportional hazards regressionMultivariable Cox regression analysisCox proportional hazards regressionSmall cell lung cancerBilateral lung involvementConsolidative thoracic radiotherapyLimited metastatic burdenMetastasis-directed radiotherapyPlatinum-doublet chemotherapyCox regression analysisMetastasis-free survivalRecurrence-free survivalTime of diagnosisProportional hazards regressionCell lung cancerLog-rank test
2022
Risk Assessment in the Molecular Era
Knowlton CA, Jimenez RB, Moran MS. Risk Assessment in the Molecular Era. Seminars In Radiation Oncology 2022, 32: 189-197. PMID: 35688517, DOI: 10.1016/j.semradonc.2022.01.005.Peer-Reviewed Original ResearchConceptsBreast-conserving surgeryClinical-pathologic featuresHormone receptor-positive diseaseLow-risk DCIS patientsLow-risk DCISAdjuvant endocrine therapyLocal control rateMajority of patientsSpecific survival outcomesPersonalized risk assessmentMolecular assaysBreast recurrenceDCIS patientsDCIS ScoreRT recommendationsDefinitive surgeryEndocrine therapyPostoperative radiotherapyPositive diseaseDuctal carcinomaSurvival outcomesControl rateInvasive cancerTreatment paradigmBreast cancer
2021
Benefit of Deep Inspiratory Breath Hold for Right Breast Cancer When Regional Lymph Nodes Are Irradiated
Peters GW, Gao SJ, Knowlton C, Zhang A, Evans SB, Higgins S, Wilson LD, Saltmarsh N, Picone M, Moran MS. Benefit of Deep Inspiratory Breath Hold for Right Breast Cancer When Regional Lymph Nodes Are Irradiated. Practical Radiation Oncology 2021, 12: e7-e12. PMID: 34508890, DOI: 10.1016/j.prro.2021.08.010.Peer-Reviewed Original ResearchConceptsRight-sided breast cancerRegional nodal irradiationLiver VBreast cancerLung VDIBH plansLiver parametersLung doseComprehensive regional nodal irradiationLeft-sided breast cancerRight breast cancerWilcoxon signed-rank testingRegional lymph nodesTotal liver volumeIpsilateral lung VLiver DHeart VNodal irradiationRBC patientsHeart doseLymph nodesInspiratory breathLiver volumeLarge cohortTreatment planOptimal Management for Residual Disease Following Neoadjuvant Systemic Therapy
Foldi J, Rozenblit M, Park TS, Knowlton CA, Golshan M, Moran M, Pusztai L. Optimal Management for Residual Disease Following Neoadjuvant Systemic Therapy. Current Treatment Options In Oncology 2021, 22: 79. PMID: 34213636, DOI: 10.1007/s11864-021-00879-4.Peer-Reviewed Original ResearchConceptsPathologic complete responseResidual cancerClinical trialsAdjuvant therapyExcellent long-term disease-free survivalLong-term disease-free survivalAxillary lymph node dissectionHuman epidermal growth factor receptor 2Early-stage breast cancerEpidermal growth factor receptor 2Post-mastectomy breastSystemic adjuvant therapyInternal mammary nodesLymph node dissectionNeoadjuvant systemic therapyDisease-free survivalGrowth factor receptor 2Minimal residual disease monitoringRecurrence-free survivalType of surgeryPivotal clinical trialsOngoing clinical trialsFactor receptor 2Residual disease monitoringAccurate prognostic estimatesCLO21-025: Benefit of Deep Inspiratory Breath Hold for Right Breast Cancer When Regional Lymph Nodes Are Irradiated
Peters G, Gao S, Knowlton C, Zhang A, Evans S, Higgins S, Wilson L, Saltmarsh N, Picone M, Moran M. CLO21-025: Benefit of Deep Inspiratory Breath Hold for Right Breast Cancer When Regional Lymph Nodes Are Irradiated. Journal Of The National Comprehensive Cancer Network 2021, 19: clo21-025. DOI: 10.6004/jnccn.2020.7707.Peer-Reviewed Original Research
2020
2019
Standard Tangential Radiation Fields Do Not Provide Incidental Coverage to the Internal Mammary Nodes
Loganadane G, Kassick M, Kann BH, Young MR, Knowlton CA, Evans SB, Higgins SA, Belkacemi Y, Potenziani M, Saltmarsh N, Wilson LD, Moran MS. Standard Tangential Radiation Fields Do Not Provide Incidental Coverage to the Internal Mammary Nodes. Practical Radiation Oncology 2019, 10: 21-28. PMID: 31394256, DOI: 10.1016/j.prro.2019.07.014.Peer-Reviewed Original ResearchConceptsInternal mammary nodesClinical target volumePlanning target volumeIMN chainMean doseTangential radiation fieldsTarget volumePostmastectomy radiationMammary nodesRadiation therapyAdjuvant whole breast radiation therapyWhole breast radiation therapyRegional nodal radiationConformal radiation therapyNodal radiationPrimary endpointMedian doseTherapeutic coverageStudy cohortTherapeutic dosesBreast cancerIncidental doseAxillary fieldKruskal-Wallis testSupraclavicular fieldPV-0045 Is proton therapy a "pro" for breast cancer? A comparison of proton vs. non-proton RT using the NCDB
Chowdhary M, Lee A, Gao S, Barry P, Diaz R, Bagadiya N, Park H, Yu J, Wilson L, Moran M, Higgins S, Knowlton C, Patel K. PV-0045 Is proton therapy a "pro" for breast cancer? A comparison of proton vs. non-proton RT using the NCDB. Radiotherapy And Oncology 2019, 133: s15. DOI: 10.1016/s0167-8140(19)30465-7.Peer-Reviewed Original ResearchPatient-Reported Outcomes and Cosmesis in a Feasibility Study of 4-Dimensional Simulated Image Guided Accelerated Partial Breast Irradiation
Rahimy E, Weidhaas J, Wei W, Lannin D, Horowitz N, Higgins S, Wilson LD, Knowlton C, Moran MS, Young MR, Killelea B, Chagpar A, Yeboa DN, Zelterman D, Evans S. Patient-Reported Outcomes and Cosmesis in a Feasibility Study of 4-Dimensional Simulated Image Guided Accelerated Partial Breast Irradiation. Practical Radiation Oncology 2019, 9: e257-e265. PMID: 30796975, DOI: 10.1016/j.prro.2019.01.013.Peer-Reviewed Original ResearchConceptsPartial breast irradiationDosimetric constraintsBreast irradiationCosmetic outcomePoor cosmesisToxicity gradeBreast cancerKarnofsky performance status scoreTarget volumeAccelerated Partial Breast IrradiationSmaller planning target volumesAcceptable cosmetic outcomeAdverse cosmetic outcomePathologic tumor sizePerformance status scoreI breast cancerBreast-conserving surgeryThree-dimensional conformalDose-volume relationshipPlanning target volumeComputed tomography simulationDaily image guidanceLocoregional recurrencePrimary endpointTumor sizeIs Proton Therapy a “Pro” for Breast Cancer? A Comparison of Proton vs. Non-proton Radiotherapy Using the National Cancer Database
Chowdhary M, Lee A, Gao S, Wang D, Barry PN, Diaz R, Bagadiya NR, Park HS, Yu JB, Wilson LD, Moran MS, Higgins SA, Knowlton CA, Patel KR. Is Proton Therapy a “Pro” for Breast Cancer? A Comparison of Proton vs. Non-proton Radiotherapy Using the National Cancer Database. Frontiers In Oncology 2019, 8: 678. PMID: 30693271, PMCID: PMC6339938, DOI: 10.3389/fonc.2018.00678.Peer-Reviewed Original ResearchLymph node irradiationNational Cancer DatabaseOverall survivalMultivariable analysisBreast cancerCancer DatabaseProton radiotherapyNon-metastatic breast cancerCox proportional hazards modelHigher heart dosesN2-N3 diseaseMultivariate logistic analysisProportional hazards modelAcademic facilitiesLogistic regression modelsHeart dosesAdjuvant radiotherapyNode irradiationHazard ratioNode positivityClinical benefitClinical trialsPRT patientsStage 0Hazards model
2018
EP-1328: Impact of deep inspiration breath hold on heart and lung dose constraints in a large breast series
Loganadane G, Kann B, Young M, Knowlton C, Higgins S, Belkacemi Y, Wilson L, Moran M. EP-1328: Impact of deep inspiration breath hold on heart and lung dose constraints in a large breast series. Radiotherapy And Oncology 2018, 127: s727-s728. DOI: 10.1016/s0167-8140(18)31638-4.Peer-Reviewed Original ResearchEP-1321: Incidental radiation dose to the internal mammary chain in a large clinical breast series
Loganadane G, Kann B, Young M, Knowlton C, Evans S, Higgins S, Belkacemi Y, Wilson L, Moran M. EP-1321: Incidental radiation dose to the internal mammary chain in a large clinical breast series. Radiotherapy And Oncology 2018, 127: s724. DOI: 10.1016/s0167-8140(18)31631-1.Peer-Reviewed Original Research